Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Acute Migraine Treatment Update

11/13/2019

 
Three new drugs are in development for the treatment of acute migraine. While many patients receive relief with a triptan, not all patients can tolerate this class of drugs or are helped by them. The triptans also have a contraindication in patients with cardiovascular disease, peripheral vascular disease, cerebrovascular disease, and uncontrolled hypertension because of the potential for ischemia. For these reasons new drugs are being developed. The investigational gepants (ubrogepant and rimegepant) and the recently approved lasmiditan (a ditan).  The gepants (ubrogepant and rimegepant) and lasmiditan do not cause vasoconstriction and may be an alternative when patients do not tolerate triptans or cannot use a triptan due to cardiovascular disease.
 
ICER released a draft review of lasmiditan, ubrogepant and rimegepant in November 2019. ICER found the drugs to be comparable to each other in efficacy, but not as efficacious as triptans. Lasmiditan, ubrogepant and rimegepant would provide a benefit for patients with cardiovascular disease that have a contraindication to triptans, were not helped by triptans or do not tolerate them. Since triptans are available as generics, ICER concludes that triptans would provide a greater benefit at a lower cost than lasmiditan, ubrogepant or rimegepant. To reach a threshold of $150,000 per quality-adjusted life year ICER estimated an annual cost of $1,850 for lasmiditan, $1,780 for rimegepant and $1,740 for ubrogepant.
​
With the lack of data to support efficacy equivalence to triptans and a higher cost than generic triptans, the role of lasmiditan, ubrogepant and rimegepant may be for the treatment of patients that require treatment beyond an NSAID or acetaminophen and are not eligible for treatment with a triptan. There is the possibility of lower prices with these drugs by Spring 2020 with PDUFA dates for ubrogepant in December 2019 and rimegepant in March 2020.

​Lasmiditan
  • Company: Eli Lilly
  • M of A: 5-HT1F receptor antagonist in the trigeminal pathway
  • ADR: dizziness, paresthesia, somnolence, fatigue, nausea, weak muscles, and hypoesthesia. Due to the occurrence of dizziness and sedation from CNS depression, patients are warned of potential impairment while taking lasmiditan and advised not to drive, operate machinery or take with alcohol or other CNS depressants for at least eight hours after taking the drug, even if they feel well enough to do so.
  • Route: Oral
  • Indication: Acute migraines, with or without aura, in adult patients. 
  • The FDA approved lasmiditan on 10/11/2019.
  • Efficacy at two hours
    • SPARTAN: 27-39% of lasmiditan patients were pain free and 41-49% were free of their most bothersome symptoms compared to 21% and 36% of placebo patients.
    • SAMURAI: 28-32% of lasmiditan patients were pain free and 41% were free of their most bothersome symptoms compared to 15% and 30% of placebo patients.
Calcitonin Gene-Related Peptide (CGRP) Antagonists
CGRP is a neuropeptide that has both cerebral arteriolar dilating and pain modulation properties.  
Decreasing CGRP inhibits vasodilation without inducing vasoconstriction. The gepants are small molecule orally administered CGRP antagonists. Merck abandoned work on two early CGRP Antagonists, telcagepant (MK-0974) and MK-3207 due to hepatotoxicity concerns, so hepatotoxicity continues to be monitored. 
 
Ubrogepant
  • Company: Allergan
  • M of A: CGRP receptor antagonist
  • ADR: Nausea, somnolence, dry mouth and dizziness
  • Route: Oral
  • Indication: Acute migraine
  • PDUFA: December 27, 2019
  • Priority Designations: None
  • Efficacy at two hours
    • ACHIEVE I: 19-21% of ubrogepant patients were pain free and 38% were free of their most bothersome symptoms compared to 12% and 28% of placebo patients.
    • Study 2: 21-22% of ubrogepant patients were pain free and 39% were free of their most bothersome symptoms compared to 14% and 27% of placebo patients.
Rimegepant
  • Company: Biohaven Pharma
  • M of A: CGRP receptor antagonist
  • ADR: nausea and urinary tract infection
  • Route: Oral
  • Indication: Acute migraine
  • PDUFA: March 16, 2020
  • Priority Designations: None
  • Efficacy
    • Study 1: 20% of rimegepant patients were pain-free and 38% were free of their most bothersome symptoms compared to 12% and 25% of placebo patients.
    • Study 2: 19% of rimegepant patients were pain-free and 37% were free of their most bothersome symptoms compared to 14% and 28% of placebo patients.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.